

Markus Magerl

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2021050/publications.pdf>

Version: 2024-02-01

140
papers

8,696
citations

46918

47
h-index

49773

87
g-index

163
all docs

163
docs citations

163
times ranked

4385
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 979-990.	2.7	33
2	The international EAACI/GA ² LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 734-766.	2.7	392
3	The international WAO/EAACI guideline for the management of hereditary angioedema – The 2021 revision and update. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 1961-1990.	2.7	153
4	Attenuated androgen discontinuation in patients with hereditary angioedema: a commented case series. <i>Allergy, Asthma and Clinical Immunology</i> , 2022, 18, 4.	0.9	5
5	The international WAO/EAACI guideline for the management of hereditary angioedema – The 2021 revision and update. <i>World Allergy Organization Journal</i> , 2022, 15, 100627.	1.6	37
6	Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet, The</i> , 2022, 399, 945-955.	6.3	28
7	Impact of lanadelumab on health-related quality of life in patients with hereditary angioedema in the HELP study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1188-1198.	2.7	28
8	The characteristics and impact of pruritus in adult dermatology patients: A prospective, cross-sectional study. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 691-700.	0.6	28
9	Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 86.	1.2	10
10	Differences and Similarities in the Mechanisms and Clinical Expression of Bradykinin-Mediated vs. Mast Cell-Mediated Angioedema. <i>Clinical Reviews in Allergy and Immunology</i> , 2021, 61, 40-49.	2.9	39
11	Analysis of genetic impact on smell impairment in patients with hereditary angioedema type 1 and 2. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 1060-1062.	0.4	0
12	Consensus on treatment goals in hereditary angioedema: A global Delphi initiative. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 1526-1532.	1.5	27
13	Mitigating Disparity in Health-care Resources Between Countries for Management of Hereditary Angioedema. <i>Clinical Reviews in Allergy and Immunology</i> , 2021, 61, 84-97.	2.9	16
14	Lanadelumab Efficacy, Safety, and Injection Interval Extension in HAE: A Real-Life Study. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3744-3751.	2.0	17
15	The Diagnostic Workup in Chronic Spontaneous Urticaria – What to Test and Why. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2274-2283.	2.0	21
16	How are patients with chronic urticaria interested in using information and communication technologies to guide their healthcare? A UCARE study. <i>World Allergy Organization Journal</i> , 2021, 14, 100542.	1.6	11
17	HAE patient self-sampling for biomarker establishment. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 399.	1.2	4
18	Automatic screening of self-evaluation apps for urticaria and angioedema shows a high unmet need. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3810-3813.	2.7	8

#	ARTICLE	IF	CITATIONS
19	Inducible Urticarias. , 2021, , 109-132.		0
20	Chronic urticaria patients are interested in apps to monitor their disease activity and control: A UCARE CURICT analysis. Clinical and Translational Allergy, 2021, 11, e12089.	1.4	9
21	Disease activity and stress are linked in a subpopulation of chronic spontaneous urticaria patients. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 224-226.	2.7	15
22	How to control recurrent angioedema using monoclonal antibody therapies?. Expert Opinion on Biological Therapy, 2020, 20, 1-4.	1.4	9
23	International Consensus on the Use of Genetics in the Management of Hereditary Angioedema. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 901-911.	2.0	43
24	Development of the Angioedema Control Testâ€”A patientâ€™reported outcome measure that assesses disease control in patients with recurrent angioedema. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1165-1177.	2.7	47
25	Effective treatment with mepolizumab in a patient with refractory Wells syndrome. JDDG - Journal of the German Society of Dermatology, 2020, 18, 737-739.	0.4	6
26	A Germany-wide survey study on the patient journey of patients with hereditary angioedema. Orphanet Journal of Rare Diseases, 2020, 15, 221.	1.2	9
27	Validation of the Angioedema Control Test (AECT)â€”A Patient-Reported Outcome Instrument for Assessing Angioedema Control. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 2050-2057.e4.	2.0	50
28	Hereditary angioedema in children and adolescents â€” A consensus update on therapeutic strategies for Germanâ€™speaking countries. Pediatric Allergy and Immunology, 2020, 31, 974-989.	1.1	16
29	A novel deep intronic SERPING1 variant as a cause of hereditary angioedema due to C1-inhibitor deficiency. Allergology International, 2020, 69, 443-449.	1.4	19
30	Definition, aims, and implementation of GA²/LEN/HAEi Angioedema Centers of Reference and Excellence. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2115-2123.	2.7	29
31	The usage, quality and relevance of information and communications technologies in patients with chronic urticaria: A UCARE study. World Allergy Organization Journal, 2020, 13, 100475.	1.6	13
32	Guideline: Hereditary angioedema due to C1 inhibitor deficiency. Allergo Journal International, 2019, 28, 16-29.	0.9	32
33	Diagnosis and treatment of chronic inducible urticaria. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 2550-2553.	2.7	26
34	Recombinant human C1 esterase inhibitor treatment for hereditary angioedema attacks in children. Pediatric Allergy and Immunology, 2019, 30, 562-568.	1.1	18
35	Immunological effects and potential mechanisms of action of autologous serum therapy in chronic spontaneous urticaria. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1747-1754.	1.3	20
36	Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1793-1802.e2.	2.0	58

#	ARTICLE	IF	CITATIONS
37	Management of patients with hereditary angioedema in Germany: comparison with other countries in the Icatibant Outcome Survey. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 163-169.	1.3	8
38	Benefit of mepolizumab treatment in a patient with chronic spontaneous urticaria. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018, 16, 477-478.	0.4	51
39	The EAACI/GA ² LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 1393-1414.	2.7	1,008
40	Executive summary of the methods report for "The EAACI/GA ² LEN/EDF/WAO Guideline for the Definition, Classification, Diagnosis and Management of Urticaria. The 2017 Revision and Update"™. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 1145-1146.	2.7	74
41	The international WAO/EAACI guideline for the management of hereditary angioedema "The 2017 revision and update. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 1575-1596.	2.7	365
42	The international WAO/EAACI guideline for the management of hereditary angioedema " the 2017 revision and update. <i>World Allergy Organization Journal</i> , 2018, 11, 5.	1.6	45
43	Epidemiology of Bradykinin-mediated angioedema: a systematic investigation of epidemiological studies. <i>Orphanet Journal of Rare Diseases</i> , 2018, 13, 73.	1.2	114
44	Nutzen von Mepolizumab bei einer Patientin mit chronischer spontaner Urtikaria. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018, 16, 476-477.	0.4	1
45	Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The "OPUS" study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 1871-1880.	2.7	31
46	Omalizumab treatment in patients with chronic inducible urticaria: A systematic review of published evidence. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 638-649.	1.5	187
47	Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 2108.	3.8	174
48	Improvement in diagnostic delays over time in patients with hereditary angioedema: findings from the Icatibant Outcome Survey. <i>Clinical and Translational Allergy</i> , 2018, 8, 42.	1.4	29
49	Targeted next-generation sequencing for the molecular diagnosis of hereditary angioedema due to C1-inhibitor deficiency. <i>Gene</i> , 2018, 667, 76-82.	1.0	32
50	Oral Plasma Kallikrein Inhibitor for Prophylaxis in Hereditary Angioedema. <i>New England Journal of Medicine</i> , 2018, 379, 352-362.	13.9	89
51	Updosing of bilastine is effective in moderate to severe chronic spontaneous urticaria: A real-life study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 2073-2075.	2.7	22
52	Short-term prophylactic use of C1-inhibitor concentrate in hereditary angioedema. <i>Annals of Allergy, Asthma and Immunology</i> , 2017, 118, 110-112.	0.5	24
53	Efficacy and Safety of an Intravenous C1-Inhibitor Concentrate for Long-Term Prophylaxis in Hereditary angioedema. <i>Allergy and Rhinology</i> , 2017, 8, ar.2017.8.0192.	0.7	21
54	Safety of C1-inhibitor concentrate use for hereditary angioedema in pediatric patients. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 1142-1145.	2.0	17

#	ARTICLE	IF	CITATIONS
55	Clinical Utility Gene Card for hereditary angioedema with normal C1 inhibitor (HAEnC1). European Journal of Human Genetics, 2017, 25, e1-e4.	1.4	9
56	Genetic Determinants of C1 Inhibitor Deficiency Angioedema Age of Onset. International Archives of Allergy and Immunology, 2017, 174, 200-204.	0.9	28
57	Hereditary Angioedema with Normal C1 Inhibitor. Immunology and Allergy Clinics of North America, 2017, 37, 571-584.	0.7	43
58	Health-related quality of life with hereditary angioedema following prophylaxis with subcutaneous C1-inhibitor with recombinant hyaluronidase. Allergy and Asthma Proceedings, 2017, 38, 143-151.	1.0	28
59	An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension. Clinical and Translational Allergy, 2017, 7, 36.	1.4	28
60	Expert Perspectives on Hereditary Angioedema: Key Areas for Advancements in Care across the Patient Journey. Allergy and Rhinology, 2016, 7, ar.2016.7.0165.	0.7	17
61	An analysis of the teaching of intravenous self-administration in patients with hereditary angio-oedema. Clinical and Experimental Dermatology, 2016, 41, 366-371.	0.6	10
62	Histamine intolerance in patients with chronic spontaneous urticaria. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1774-1777.	1.3	29
63	Daily subcutaneous administration of human C1 inhibitor in a child with hereditary angioedema type 1. Pediatric Allergy and Immunology, 2016, 27, 223-224.	1.1	5
64	Definition, aims, and implementation of ² GA</sup> Urticaria Centers of Reference and Excellence. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 1210-1218.	2.7	110
65	The Angioedema Quality of Life Questionnaire (AE-QoL) assessment of sensitivity to change and minimal clinically important difference. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 1203-1209.	2.7	92
66	Subcutaneous administration of human C1 inhibitor with recombinant human hyaluronidase in patients with hereditary angioedema. Allergy and Asthma Proceedings, 2016, 37, 489-500.	1.0	10
67	Prophylaxis of hereditary angioedema attacks: A randomized trial of oral plasma kallikrein inhibition with avoralstat. Journal of Allergy and Clinical Immunology, 2016, 138, 934-936.e5.	1.5	25
68	C1 Inhibitor for Routine Prophylaxis in Patients with Hereditary Angioedema: Interim Results from a European Registry Study. Journal of Allergy and Clinical Immunology, 2016, 137, AB251.	1.5	5
69	The definition, diagnostic testing, and management of chronic inducible urticarias - The EAACI/GA² LEN/EDF/UNEV consensus recommendations 2016 update and revision. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 780-802.	2.7	268
70	Subcutaneous self-injections of C1 inhibitor: an effective and safe treatment in a patient with hereditary angio-oedema. Clinical and Experimental Dermatology, 2016, 41, 91-93.	0.6	9
71	Prophylaxis in hereditary angioedema (HAE) with C1 inhibitor deficiency. JDDG - Journal of the German Society of Dermatology, 2016, 14, 266-275.	0.4	16
72	Prophylaxe beim hereditären Angioödem (HAE) mit C1-Inhibitormangel. JDDG - Journal of the German Society of Dermatology, 2016, 14, 266-276.	0.4	8

#	ARTICLE	IF	CITATIONS
73	Safety and Usage of C1-Inhibitor in Hereditary Angioedema: Berinert Registry Data. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2016, 4, 963-971.	2.0	50
74	BCX4161, an Oral Kallikrein Inhibitor, Showed Significant Benefits on Reducing Disease Burden and Improving Quality of Life in Subjects with Hereditary Angioedema in the Opus-1 Study. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, AB278.	1.5	4
75	Efficacy Correlates with Plasma Levels in Opus-1, a Proof-of-Concept Study of Oral Kallikrein Inhibitor BCX4161 As a Prophylaxis Against Attacks of Hereditary Angioedema (HAE). <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, AB192.	1.5	5
76	Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1-inhibitor concentrate. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2015, 70, 1319-1328.	2.7	59
77	Pharmacokinetics of Subcutaneous C1 Esterase Inhibitor (human) with Recombinant Human Hyaluronidase for the Prevention of Angioedema Attacks in Patients with Hereditary Angioedema. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, AB192.	1.5	1
78	An improved Peltier effect-based instrument for critical temperature threshold measurement in cold- and heat-induced urticaria. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 2043-2045.	1.3	35
79	<i>F12</i> 46C/T polymorphism as modifier of the clinical phenotype of hereditary angioedema. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2015, 70, 1661-1664.	2.7	42
80	Validation of a simplified provocation instrument for diagnosis and threshold testing of symptomatic dermographism. <i>Clinical and Experimental Dermatology</i> , 2015, 40, 399-403.	0.6	25
81	Hereditary angioedema: Molecular and clinical differences among European populations. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 570-573.e10.	1.5	63
82	Subcutaneous Human C1-Inhibitor with Recombinant Human Hyaluronidase for the Prevention of Angioedema Attacks in Patients with Hereditary Angioedema: Results of a Randomized, Double-Blind, Dose-Ranging, Crossover Study. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, AB278.	1.5	4
83	Characterization of prodromal symptoms in a large population of patients with hereditary angio-oedema. <i>Clinical and Experimental Dermatology</i> , 2014, 39, 298-303.	0.6	44
84	Revisions to the international guidelines on the diagnosis and therapy of chronic urticaria. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013, 11, 971-978.	0.4	39
85	Hereditary angioedema with C1 inhibitor deficiency: delay in diagnosis in Europe. <i>Allergy, Asthma and Clinical Immunology</i> , 2013, 9, 29.	0.9	107
86	Miltefosine: a novel treatment option for mast cell-mediated diseases. <i>Journal of Dermatological Treatment</i> , 2013, 24, 244-249.	1.1	10
87	Randomized, double-blind, placebo-controlled study of safety and efficacy of miltefosine in antihistamine-resistant chronic spontaneous urticaria. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, e363-9.	1.3	23
88	Rupatadine improves quality of life in mastocytosis: a randomized, double-blind, placebo-controlled trial. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2013, 68, 949-952.	2.7	46
89	Practical algorithm for diagnosing patients with recurrent wheals or angioedema. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2013, 68, 816-819.	2.7	53
90	Practical Approach to Self-Administration of Intravenous C1-INH Concentrate: A Nursing Perspective. <i>International Archives of Allergy and Immunology</i> , 2013, 161, 17-20.	0.9	21

#	ARTICLE	IF	CITATIONS
91	Development, validation, and initial results of the Angioedema Activity Score. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 1185-1192.	2.7	147
92	A novel, simple, validated and reproducible instrument for assessing provocation threshold levels in patients with symptomatic dermographism. Clinical and Experimental Dermatology, 2013, 38, 360-366.	0.6	35
93	Hereditary angioedema with normal C1 inhibitor function: Consensus of an international expert panel. Allergy and Asthma Proceedings, 2012, 33, 145-156.	1.0	142
94	Development and construct validation of the angioedema quality of life questionnaire. Allergy: European Journal of Allergy and Clinical Immunology, 2012, 67, 1289-1298.	2.7	182
95	Hereditary angioedema (HAE) in children and adolescents—a consensus on therapeutic strategies. European Journal of Pediatrics, 2012, 171, 1339-1348.	1.3	80
96	WAO Guideline for the Management of Hereditary Angioedema. World Allergy Organization Journal, 2012, 5, 182-199.	1.6	264
97	Critical temperature threshold measurement for cold urticaria: a randomized controlled trial of H ₁ -antihistamine dose escalation. British Journal of Dermatology, 2012, 166, 1095-1099.	1.4	53
98	Adaptation and initial results of the Polish version of the GA2LEN Chronic Urticaria Quality Of Life Questionnaire (CU-Q2oL). Journal of Dermatological Science, 2011, 62, 36-41.	1.0	28
99	Anti-Immunoglobulin E Treatment of Patients with Recalcitrant Physical Urticaria. International Archives of Allergy and Immunology, 2011, 154, 177-180.	0.9	133
100	Omalizumab - an effective and safe treatment of therapy-resistant chronic spontaneous urticaria. Allergy: European Journal of Allergy and Clinical Immunology, 2011, 66, 303-305.	2.7	61
101	New topics in bradykinin research. Allergy: European Journal of Allergy and Clinical Immunology, 2011, 66, 1397-1406.	2.7	146
102	Treatment of notalgia paraesthetica with an 8% capsaicin patch. British Journal of Dermatology, 2011, 165, 1359-1361.	1.4	18
103	Successful treatment of an acute attack of acquired angioedema with the bradykinin-B2-receptor antagonist icatibant. Journal of the European Academy of Dermatology and Venereology, 2011, 25, 119-120.	1.3	21
104	Long-term prophylaxis of hereditary angioedema with androgen derivatives: a critical appraisal and potential alternatives. JDDG - Journal of the German Society of Dermatology, 2011, 9, 99-107.	0.4	28
105	Langzeitprophylaxe des hereditären Angioödems mit Androgenderivaten: kritische Bewertung und mögliche Alternativen. JDDG - Journal of the German Society of Dermatology, 2011, 9, 99-108.	0.4	18
106	Chronic Spontaneous Urticaria: How to Assess Quality of Life in Patients Receiving Treatment. Archives of Dermatology, 2011, 147, 1221.	1.7	22
107	High Prevalence of Mental Disorders and Emotional Distress in Patients with Chronic Spontaneous Urticaria. Acta Dermato-Venereologica, 2011, 91, 557-561.	0.6	110
108	Successful treatment of hereditary angioedema with bradykinin B2-receptor antagonist icatibant. JDDG - Journal of the German Society of Dermatology, 2010, 8, 272-274.	0.4	5

#	ARTICLE	IF	CITATIONS
109	Erfolgreiche Behandlung des hereditären Angioödems mit dem Bradykinin-B2-Rezeptor-Antagonisten Icatibant. JDDG - Journal of the German Society of Dermatology, 2010, 8, 272-274.	0.4	7
110	Hereditary angioedema: an update on available therapeutic options. JDDG - Journal of the German Society of Dermatology, 2010, 8, 663-672.	0.4	16
111	Hereditäres Angioödem: Update zu verfügbaren Therapieoptionen. JDDG - Journal of the German Society of Dermatology, 2010, 8, 663-673.	0.4	14
112	Results and relevance of critical temperature threshold testing in patients with acquired cold urticaria. British Journal of Dermatology, 2010, 162, 198-200.	1.4	49
113	Topical sodium cromoglicate relieves allergen- and histamine-induced dermal pruritus. British Journal of Dermatology, 2010, 162, 674-676.	1.4	59
114	Effects of a pseudoallergen-free diet on chronic spontaneous urticaria: a prospective trial. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 78-83.	2.7	102
115	Antihistamine-resistant urticaria factitia successfully treated with anti-immunoglobulin E therapy. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 1494-1495.	2.7	46
116	Effective treatment of therapy-resistant chronic spontaneous urticaria with omalizumab. Journal of Allergy and Clinical Immunology, 2010, 126, 665-666.	1.5	59
117	Prevention of signs and symptoms of dermographic urticaria by single-dose ebastine 20 mg. Clinical and Experimental Dermatology, 2009, 34, e137-e140.	0.6	21
118	Mast cells determine the magnitude of bacterial toxin-induced skin inflammation. Experimental Dermatology, 2009, 18, 160-166.	1.4	22
119	Patients with chronic urticaria exhibit increased rates of sensitisation to <i>Candida albicans</i> , but not to common moulds. Mycoses, 2009, 52, 334-338.	1.8	25
120	The German version of the chronic urticaria quality-of-life questionnaire: factor analysis, validation, and initial clinical findings. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 927-936.	2.7	145
121	The definition and diagnostic testing of physical and cholinergic urticarias – EAACI/GA ² LEN/EDF/UNEV consensus panel recommendations. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 1715-1721.	2.7	143
122	Frequency and clinical implications of skin autoreactivity to serum versus plasma in patients with chronic urticaria. Journal of Allergy and Clinical Immunology, 2009, 123, 705-706.	1.5	67
123	Suppression of histamine- and allergen-induced skin reactions: comparison of first- and second-generation antihistamines. Annals of Allergy, Asthma and Immunology, 2009, 102, 495-499.	0.5	17
124	Prevalence and relevance of skin autoreactivity in chronic urticaria. Expert Review of Dermatology, 2009, 4, 655-663.	0.3	3
125	Non-pathogenic commensal <i>Escherichia coli</i> bacteria can inhibit degranulation of mast cells. Experimental Dermatology, 2008, 17, 427-435.	1.4	47
126	Successful treatment of solar urticaria with anti-immunoglobulin E therapy. Allergy: European Journal of Allergy and Clinical Immunology, 2008, 63, 1563-1565.	2.7	149

#	ARTICLE	IF	CITATIONS
127	Mast cell-driven skin inflammation is impaired in the absence of sensory nerves. <i>Journal of Allergy and Clinical Immunology</i> , 2008, 121, 955-961.	1.5	75
128	Control of <i>Pseudomonas aeruginosa</i> Skin Infections in Mice Is Mast Cell-Dependent. <i>American Journal of Pathology</i> , 2007, 170, 1910-1916.	1.9	80
129	Successful treatment of delayed pressure urticaria with anti-TNF- α . <i>Journal of Allergy and Clinical Immunology</i> , 2007, 119, 752-754.	1.5	81
130	Acquired cold urticaria symptoms can be safely prevented by ebastine. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2007, 62, 1465-1468.	2.7	38
131	Acquired cold urticaria: clinical picture and update on diagnosis and treatment. <i>Clinical and Experimental Dermatology</i> , 2007, 32, 241-245.	0.6	105
132	Autologous Whole Blood Injections to Patients with Chronic Urticaria and a Positive Autologous Serum Skin Test: A Placebo-Controlled Trial. <i>Dermatology</i> , 2006, 212, 150-159.	0.9	120
133	Quality of life in patients with chronic urticaria is differentially impaired and determined by psychiatric comorbidity. <i>British Journal of Dermatology</i> , 2006, 154, 294-298.	1.4	189
134	Limitations of human occipital scalp hair follicle organ culture for studying the effects of minoxidil as a hair growth enhancer. <i>Experimental Dermatology</i> , 2004, 13, 635-642.	1.4	31
135	Peltier effect-based temperature challenge: An improved method for diagnosing cold urticaria. <i>Journal of Allergy and Clinical Immunology</i> , 2004, 114, 1224-1225.	1.5	63
136	Plasticity and Cytokinetic Dynamics of the Hair Follicle Mesenchyme During the Hair Growth Cycle: Implications for Growth Control and Hair Follicle Transformations. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 2003, 8, 80-86.	0.8	51
137	Plasticity and Cytokinetic Dynamics of the Hair Follicle Mesenchyme: Implications for Hair Growth Control. <i>Journal of Investigative Dermatology</i> , 2003, 120, 895-904.	0.3	135
138	Simple and rapid method to isolate and culture follicular papillae from human scalp hair follicles. <i>Experimental Dermatology</i> , 2002, 11, 381-385.	1.4	84
139	Patterns of Proliferation and Apoptosis during Murine Hair Follicle Morphogenesis. <i>Journal of Investigative Dermatology</i> , 2001, 116, 947-955.	0.3	83
140	Searching for Genetic Biomarkers for Hereditary Angioedema Due to C1-Inhibitor Deficiency (C1-INH-HAE). <i>Frontiers in Allergy</i> , 0, 3, .	1.2	2